Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
نویسندگان
چکیده
منابع مشابه
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
The discovery of anaplastic lymphoma kinase (ALK) gene rearrangements and the development of tyrosine kinase inhibitors (TKI) that target them have achieved unprecedented success in the management of patients with ALK-positive non-small cell lung cancer (NSCLC). Despite the high efficacy of crizotinib, the first oral ALK TKI approved for the treatment of ALK-positive NSCLC, almost all patients ...
متن کاملAfatinib treatment in advanced non-small cell lung cancer.
Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients remains poor. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have however provided a new therapeutic option in this disease setting and EGFR mutation testing is now routine practice for newly diagnosed NSCLC patients. A proportion ...
متن کاملMultimodality treatment in locally advanced non-small cell lung cancer.
Prognosis in patients with locally advanced non-small cell lung cancer (NSCLC) is poor (five year survival rate of 5% [1]). Radiotherapy (RT), chemotherapy (CT) and surgery (S), as single modality therapeutical approaches are unable to eradicate locoregional disease and to control systemic microscopic disease. Concurrent chemoradiation (CTRT) is at present time deemed to be the standard of care...
متن کاملTreatment paradigms in advanced non-small-cell lung cancer.
Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly impr...
متن کاملTreatment of advanced non small cell lung cancer.
Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer (NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of patients will be diagnosed with non operable, advanced-stage disease. Palliative chemotherapy and/or radiotherapy represent the standard of care of this disease. Platinum based doublets with third generation agents are consid...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer and Metastasis Reviews
سال: 2016
ISSN: 0167-7659,1573-7233
DOI: 10.1007/s10555-016-9612-6